Azor and Heart attack - a phase IV clinical study of FDA data

Summary:

Heart attack is reported as a side effect among people who take Azor (amlodipine besylate; olmesartan medoxomil), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Plavix, and have Cardiac disorder.

The phase IV clinical study analyzes which people have Heart attack when taking Azor. It is created by eHealthMe based on reports of 3,584 people who have side effects when taking Azor from the FDA, and is updated regularly.

What is Azor?

Azor has active ingredients of amlodipine besylate; olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 3,922 Azor users. Check the latest studies of Azor.

What is Heart attack?

Heart attack is found to be associated with 2,509 drugs and 3,289 conditions by eHealthMe. Check the latest studies of Heart attack.

On May, 07, 2026

3,584 people reported to have side effects when taking Azor.
Among them, 27 people (0.75%) have Heart attack.

Among these 27 people:

* Approximation only. Some reports may have incomplete information.

Do you take Azor and have Heart attack?

- Check whether Heart attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Azor:

Azor (3,922 reports)

Heart attack treatments and more:

Heart attack (266,143 reports)

How severe was Heart attack and when was it recovered:

Heart attack in Azor

Expand to all the drugs that have ingredients of amlodipine besylate; olmesartan medoxomil:

Heart attack and drugs with ingredients of amlodipine besylate; olmesartan medoxomil (23 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Azor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Heart attack:

Heart attack (2,509 drugs)

Browse all the conditions that are associated with Heart attack:

Heart attack (3,289 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on amlodipine besylate; olmesartan medoxomil (the active ingredients of Azor) and Azor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.